These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
663 related articles for article (PubMed ID: 15703423)
1. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422 [TBL] [Abstract][Full Text] [Related]
3. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Paltiel AD; Walensky RP; Schackman BR; Seage GR; Mercincavage LM; Weinstein MC; Freedberg KA Ann Intern Med; 2006 Dec; 145(11):797-806. PubMed ID: 17146064 [TBL] [Abstract][Full Text] [Related]
4. Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Walensky RP; Weinstein MC; Kimmel AD; Seage GR; Losina E; Sax PE; Zhang H; Smith HE; Freedberg KA; Paltiel AD Am J Med; 2005 Mar; 118(3):292-300. PubMed ID: 15745728 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720 [TBL] [Abstract][Full Text] [Related]
6. The cost effectiveness of combination antiretroviral therapy for HIV disease. Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160 [TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of expanded HIV screening in the United States. Lucas A; Armbruster B AIDS; 2013 Mar; 27(5):795-801. PubMed ID: 23169333 [TBL] [Abstract][Full Text] [Related]
8. Who should be screened for HIV infection? A cost-effectiveness analysis. McCarthy BD; Wong JB; Muñoz A; Sonnenberg FA Arch Intern Med; 1993 May; 153(9):1107-16. PubMed ID: 8481077 [TBL] [Abstract][Full Text] [Related]
9. The lifetime cost of current human immunodeficiency virus care in the United States. Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130 [TBL] [Abstract][Full Text] [Related]
10. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Sax PE; Islam R; Walensky RP; Losina E; Weinstein MC; Goldie SJ; Sadownik SN; Freedberg KA Clin Infect Dis; 2005 Nov; 41(9):1316-23. PubMed ID: 16206108 [TBL] [Abstract][Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. Goldie SJ; Kuntz KM; Weinstein MC; Freedberg KA; Welton ML; Palefsky JM JAMA; 1999 May; 281(19):1822-9. PubMed ID: 10340370 [TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA. Juusola JL; Brandeau ML; Long EF; Owens DK; Bendavid E AIDS; 2011 Sep; 25(14):1779-87. PubMed ID: 21716076 [TBL] [Abstract][Full Text] [Related]
13. Screening for proteinuria in US adults: a cost-effectiveness analysis. Boulware LE; Jaar BG; Tarver-Carr ME; Brancati FL; Powe NR JAMA; 2003 Dec; 290(23):3101-14. PubMed ID: 14679273 [TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Long EF; Brandeau ML; Owens DK Ann Intern Med; 2010 Dec; 153(12):778-89. PubMed ID: 21173412 [TBL] [Abstract][Full Text] [Related]
15. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness. Weinstein MC; Goldie SJ; Losina E; Cohen CJ; Baxter JD; Zhang H; Kimmel AD; Freedberg KA Ann Intern Med; 2001 Mar; 134(6):440-50. PubMed ID: 11255519 [TBL] [Abstract][Full Text] [Related]
16. HIV screening via fourth-generation immunoassay or nucleic acid amplification test in the United States: a cost-effectiveness analysis. Long EF PLoS One; 2011; 6(11):e27625. PubMed ID: 22110698 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M; PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449 [TBL] [Abstract][Full Text] [Related]
18. Cost and cost-effectiveness of antiretroviral therapy for HIV infection in Singapore. Paton NI; Chapman CA; Sangeetha S; Mandalia S; Bellamy R; Beck EJ Int J STD AIDS; 2006 Oct; 17(10):699-705. PubMed ID: 17059641 [TBL] [Abstract][Full Text] [Related]
19. How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings. Farnham PG; Sansom SL; Hutchinson AB Med Decis Making; 2012; 32(3):459-69. PubMed ID: 22247422 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of targeted human immunodeficiency virus screening in an urban emergency department. Dowdy DW; Rodriguez RM; Hare CB; Kaplan B Acad Emerg Med; 2011 Jul; 18(7):745-53. PubMed ID: 21762236 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]